Naibec Achieves Joint Research Proposal Success with Global Pharmaceutical Companies at Bio USA

[Asia Economy Reporter Hyunseok Yoo] Naivek, a peptide fusion bio-specialized company, announced on the 21st that it received multiple joint research proposals from global pharmaceutical companies for various pipelines, including the ‘K-RAS targeted anticancer drug,’ at the ‘2021 BIO International Convention (BIO USA).’

Naivek presented preclinical efficacy results of its self-developed ‘K-RAS targeted anticancer drug.’ Not only existing partner pharmaceutical companies but also numerous global pharmaceutical and biotech companies showed great interest in Naivek’s K-RAS research results, proposing joint research. Global pharmaceutical companies highly evaluated not only the efficacy results but also the fact that Naivek possesses various K-RAS pipelines, including small molecule compounds, the proprietary NIPEP-TPP based PROTAC system, and antibody/genomic medicines.

Discussions were also held with global pharmaceutical companies regarding ‘gene drug delivery systems.’ Targeting mRNA therapeutic research companies and siRNA therapeutic companies, which have rapidly emerged as COVID-19 treatments, Naivek demonstrated that its gene drug delivery system has superior stability and in vivo drug delivery efficiency compared to the existing ‘LNP delivery system,’ resulting in higher therapeutic efficacy. This achievement led to receiving about 10 joint research proposals related to gene drug delivery systems.

Requests for joint research on major pipelines under development also continued. Regarding the ‘pulmonary fibrosis treatment (NIPEP-PF),’ Naivek received two joint research proposals: one for an expansion study applying the pulmonary fibrosis treatment to renal fibrosis, and another for applying it to pulmonary arterial hypertension treatment. For the ‘inflammatory bowel disease treatment (NIPEP-IBD),’ additional data was requested on research results showing increased therapeutic effects by enhancing colon delivery efficiency through oral administration.

The company explained that these pipelines have a high possibility of technology transfer through joint research. Since the inflammatory bowel disease treatment is a continuation of joint research with ‘Intract Pharma’ last year, the likelihood of signing a technology transfer contract is high.

A Naivek official stated, “Since BIO USA was held online again this year as last year, follow-up discussions are ongoing without time and space constraints until the end of this month,” adding, “Meetings with global pharmaceutical companies will continue regarding the company’s gene and antibody drug delivery platforms, K-RAS targeted anticancer drugs, and pulmonary fibrosis and inflammatory disease treatment pipelines.”

He continued, “Most of the company’s pipelines received great interest and attention at this BIO USA,” and added, “We expect concrete results related to joint research and development and technology transfer through additional discussions with global pharmaceutical companies.”

This content was produced with the assistance of AI translation services.